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Abstract 
BACKGROUND: Henoch- schonlein purpura (HSP) is an IgA- mediated systemic small vessel vasculitis. It is the 
most common form of systemic vasculitis in children. 
CASE: A 9 years old girl admitted to the hospital with chief complain of purplish red rash on both legs since 
approximately 1 week with painful knees and ankles that make the patient unable to walk. The patient was 
diagnosed with HSP and was treated with corticosteroid and analgesics. The patients only stayed for 2 nights at 
the hospital and discharged from the hospital with the ability to walk and experience no pain.  
CONCLUSION: The role of corticosteroids in the treatment of HSP is still controversial. But from various 
research, we can conclude that the role of corticosteroid in HSP is as a symptom reliever (reduce abdominal pain 
and arthritis), but does not slow the progression of renal disease. 
 
 
 
 
 
 
 
 
Introduction 
 
Henoch Schonlein Purpura (HSP) is an IgA-
mediated systemic small vessel vasculitis with a 
predilection for the skin, gastrointestinal tract, joints, 
and kidneys [1]. It is characterised by palpable 
purpura (without thrombocytopenia), abdominal pain, 
and arthritis. HSP is a self-limiting disease but can 
cause complication such as gastrointestinal 
haemorrhage, intussusception and end-stage renal 
disease (ESRD) [2]. Renal involvement in HSP affects 
20-70% of patients and ranges in severity from 
microscopic hematuria with or without proteinuria to a 
nephritic/ nephrotic pattern with associated renal 
failure.in the majority of patients the outcome is 
excellent, with the incidence of severe long-term 
morbidity/ mortality being less than 5% [3]. 
  
Case Report 
 
A 9 years old girl admitted to the hospital with 
chief complain of purplish red rash on both legs since 
approximately 1 week. The rash came with painful 
joints on the knees and ankles that make the patient 
unable to walk for several days. No symptom of 
abdominal pain and the common cold. No fever and 
bloody stool/ rain were reported. From physical 
examination: composmentis, BP 100/70, HR 80 bpm, 
RR 18 times per minute, and temperature 36.5°C. 
Physical examination from head to toe, there is a 
manifestation of a red purplish rash (purpura) on both 
of the legs below the knees, no swelling, but the 
reduced movement of the legs due to painful joints. 
No abdominal tenderness present.  
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Figure 1: Purpura on the leg 
 
Routine laboratory test was performed, from 
the complete blood count (CBC) can be seen elevated 
thrombocyte count just a little (380.000 / ul), normal 
prothrombin time (PT) and activated partial 
thromboplastin time (aPTT), normal creatinine and 
ureum, but there is proteinuria in the urinalysis with no 
hematuria nor microhematuria. The patient was given 
medication with oral Prednisone 3 x 15 mg and 
ibuprofen syrup 3 x 6.25 ml. After the treatment, the 
painful knees disappear, but the rash still exists. And 
the patient was discharged from the hospital after 2 
night's stay in the hospital with better clinical 
manifestation. 
 
 
Discussion 
 
Henoch Schonlein purpura is a self-limiting 
condition, usually resolving within 6 to 8 weeks. In 
patients with HSP, immunoglobulin A (IgA) immune 
complexes are deposited in the small vessels, which 
causes petechiae and palpable purpura. All HSP 
patients develop a nonpruritic rash that starts briefly 
as an erythematous papule or urticarial wheels and 
then matures into crops of petechiae and purpura. 
Purpura is defined as nonblanching cutaneous 
haemorrhages. The lesions change from red to purple 
to rash coloured before fading over approximately 10 
days. The rash is most commonly located in 
dependent areas that are subject to pressure such as 
the lower extremities, belt line and buttocks. Non-
Migratory arthritis occurs in 75% of patients. The 
knees and ankles are more commonly involved than 
small joints. The arthritis symptoms include swelling, 
warmth, and tenderness. Abdominal pain occurs 60-
65% of patients and can mimic an acute abdomen in 
terms of severity [4].
 
According to the European 
League Against Rheumatism (EULAR) and Paediatric 
Rheumatology European Society (PRES), the 
diagnosis should be based on the finding of palpable 
purpura in the presence of at least one of the following 
criteria, namely, diffuse abdominal pain, arthritis or 
arthralgia, renal involvement (hematuria and/or 
proteinuria), and a biopsy showing predominant IgA 
deposition [1].  
In this case, the patient has a purplish red 
rash (purpura) on both of the legs below the knees 
with non-migratory arthritis on the knees and ankles. 
Diagnosis Criteria for HSP according to International 
Consensus Conference 2006 are palpable purpura in 
the presence of one or more of the following: Diffuse 
abdominal pain; any biopsy showing predominant 
immunoglobulin A deposition; arthritis (acute, any 
joint) or arthralgia; and renal involvement (any 
hematuria or proteinuria) [4]. 
In most cases, HSP is mild and self-limiting, 
requiring only symptomatic treatment. Bed rest and 
analgesics may be required for those with arthralgia or 
abdominal pain. The skin manifestations rarely need 
treatment [5]. The goals of treating HSP are to relieve 
acute symptoms, prevent short-term morbidity (such 
as abdominal complications) and prevent chronic 
renal insufficiency. Because HSP is characterised by 
leukocyte infiltration of the blood vessel walls along 
with with immunoglobulin A disposition, and because 
corticosteroids inhibit inflammatory process, early 
treatment with corticosteroids has been postulated to 
be effective for all 3 therapeutic goals, but still much 
controversy remains [2]. There is no consensus 
regarding the indication of steroid use in HSP, but 
there were several studies that found the efficacy of 
corticosteroid for HSP. 
According to Reamy et all, Oral prednisone at 
1 to 2 mg per kg daily for two weeks has been used to 
treat moderate to severe abdominal and joint 
symptoms. A double-blind, randomised trial found that 
early treatment with prednisone reduced abdominal 
and joint pain severity in children. Although 
prednisone did not prevent renal disease. A meta-
analysis found that corticosteroid use in children with 
HSP reduced the mean time to resolution of 
abdominal pain [4]. Bluman et all stated that current 
evidence does not support universal treatment of HSP 
with corticosteroids, as they do not appear to prevent 
the onset of renal disease or abdominal 
complications. However, corticosteroids do seem to 
have a role in the symptomatic management of HSP, 
specifically in treating abdominal pain, arthralgia and 
purpura [6], [7].  
A study by Welch shows that steroids had no 
apparent effect on the development of nephritis, 
although there was a tendency for the renal disease to 
“resolve” more readily in the treated group [8].
 
A 
double-blind, randomised trial by
 
Ronkainen J et all 
found that early treatment with prednisone reduced 
abdominal and joint pain severity in children [9]. But, 
from a recent large scale, RCT found that steroid 
treatment does not reduce the incidence and severity 
of nephropathy in patients with HSP [3].
 
It is supported 
by the study from Huber et al. who did not find any 
difference between the corticosteroid group and 
control group [11]. In this case, the patient was given 
Kurnia et al. Henoch - Schonlein Purpura in Children: The Role of Corticosteroids 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci.                                                                                                                                                                                                         3 
 
corticosteroid, and the painful joints disappear within 1 
day; although, the purplish red rash did not diminish. 
From the explanation above, the patient was 
having a Henoch Schonlein Purpura with the symptom 
of purpura on both legs, with arthritis on the knee and 
ankle that make her unable to walk with proteinuria in 
the urinalysis. She was treated with prednisone orally, 
and the next day the pain is gone. From many studies, 
it can be concluded that the role of corticosteroid is to 
relieve the abdominal pain and arthritis; but it is not to 
cure the HSP itself nor prevent the renal disease; 
therefore, corticosteroids were used just as a 
symptom reliever.  
 
 
References 
 
1. Leung AKC, Hon, KL, Barankin B. Henoch schonlein purpura in 
children. Asian Journal of Clinical Pediatrics and Neonatology. 
2016. 
2. Weiss PF, Feinstein JA, Luan X, Burnham JM, Feudtner C. 
Effects of corticosteroid on henoch schonlein purpura: a systematic 
review. 2007. https://doi.org/10.1542/peds.2007-0667 
PMid:17974746 PMCid:PMC3525094 
 
3. Dudley J, Smith G, Edwards AL, Bayliss K, Pike K, Tizard J. 
Randomised, double-blind, placebo-controlled trial to determine 
whether steroids reduce the incidence and severity of nephropathy 
in henoch-scholein purpura (hsp). United Kingdom: Bristol Royal 
University Hospital for Children, 2013. 
 
4. Reamy BV, Williams PM. Henoch schonlein purpura. Maryland: 
American Academy of Family Physicians. 2009.  
5. Jauhola O. Henoch schonlein purpura in children. University of 
Oulu, 2012.  
6. Bluman J, Goldman RD. Henoch scholein purpura in children 
limited benefit of corticosteroids. Canada: College of Family 
Physicians of Canada. 2014. 
 
7. Mccarthy HJ, Tizard EJ. Clinical practice: diagnosis and 
management of henoch-scholein purpura. European Journal of 
Pediatrics. 2009. https://doi.org/10.1007/s00431-009-1101-2 
PMid:20012647  
 
8. Welch TR. Steroids in hsp. The Journal of Pediatrics. 2006. 
 
9. Ronkainen J, Koskimies O, Ala-Houhala M, et al. Early 
prednisone therapy in Henoch-Schönlein purpura: a randomized, 
double-blind, placebo-controlled trial. J Pediatr. 2006; 149(2):241-
247. https://doi.org/10.1016/j.jpeds.2006.03.024 PMid:16887443  
 
10. Huber AM, King J, McLaine P, Klassen T, Pothos M. A ran- 
domized, placebo-controlled trial of prednisone in early He- noch 
Scho  nlein purpura [ISRCTN85109383]. BMC Med. 2004; 2:7. 
https://doi.org/10.1186/1741-7015-2-7 PMid:15059282 
PMCid:PMC400510 
 
 
